GWP42003 symptomatic treatment of ulcerative colitis.
A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis. A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the sympto ...
Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative colitis MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative ...
Product Code: GWP42003 INN or Proposed INN: Not Applicable Other descriptive name: CANNABIDIOL
GWP42003 symptomatic treatment of ulcerative colitis.
A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis. A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the sympto ...
Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative ...
Product Code: GWP42003 INN or Proposed INN: Not applicable Other descriptive name: CANNABIDIOL
GW Pharma Ltd.
NULL
Not Recruiting
Female: yes Male: yes
62
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...